Moroccan pharmaceutical group Laprophan has finalized its first European acquisition, taking a majority stake in Swiss company Rivopharm, according to a statement released on June 18, 2026. The deal marks a significant expansion for the Casablanca-based laboratory into the European market.
Rivopharm, based in Switzerland, specializes in niche pharmaceutical products, including specific medications. The acquisition was confirmed by both companies, though financial terms were not disclosed.
This move aligns with Laprophan's strategy to strengthen its international presence and diversify its portfolio. The company has been active in the Moroccan pharmaceutical sector for decades and now seeks to leverage Rivopharm's expertise in specialized medicines.
The transaction is subject to customary regulatory approvals and is expected to close in the coming months. Laprophan stated that Rivopharm will continue to operate under its existing management team.
